References
1 Tafakori Delbari M, Cheraghi T, Yazdani R, et al. Clinical Manifestations, Immunological Characteristics and Genetic Analysis of Patients with Hyper-Immunoglobulin M Syndrome in Iran. Int Arch Allergy Immunol . 2019;180:52-63.
2 Moazzami B, Yazdani R, Azizi G, et al. Respiratory Complications in Patients with Hyper IgM Syndrome. J Clin Immunol . 2019;39:557-568.
3 Yazdani R, Fekrvand S, Shahkarami S, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clin Immunol . 2019;198:19-30.
4 Meng X, Yang B, Suen WC. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome. Innate Immun . 2018;24:4-10.
5 Aghamohammadi A, Parvaneh N, Rezaei N, et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations.J Clin Immunol . 2009;29:769-776.
6 Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol . 2018;38:96-128.
7 Matamoros Flori N, Mila Llambi J, Espanol Boren T, Raga Borja S, Fontan Casariego G. Primary immunodeficiency syndrome in Spain: first report of the National Registry in Children and Adults. J Clin Immunol . 1997;17:333-339.
8 Tsai HY, Yu HH, Chien YH, et al. X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients. J Microbiol Immunol Infect . 2015;48:113-118.
9 Qamar N, Fuleihan RL. The hyper IgM syndromes. Clin Rev Allergy Immunol . 2014;46:120-130.
10 Picard C, Al-Herz W, Bousfiha A, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol . 2015;35:696-726.
11 Madkaikar M, Gupta M, Chavan S, et al. X-linked hyper IgM syndrome: clinical, immunological and molecular features in patients from India.Blood Cells Mol Dis . 2014;53:99-104.
12 Ochs HD. Patients with abnormal IgM levels: assessment, clinical interpretation, and treatment. Ann Allergy Asthma Immunol . 2008;100:509-511.
13 Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr . 1997;131:47-54.
14 Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.Medicine (Baltimore) . 2003;82:373-384.
15 Cabral-Marques O, Klaver S, Schimke LF, et al. First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes.J Clin Immunol . 2014;34:146-156.
16 de la Morena MT, Leonard D, Torgerson TR, et al. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. J Allergy Clin Immunol . 2017;139:1282-1292.
17 Kutukculer N, Aksoylar S, Kansoy S, Cetingul N, Notarangelo LD. Outcome of hematopoietic stem cell transplantation in hyper-IgM syndrome caused by CD40 deficiency. J Pediatr . 2003;143:141-142.
18 Karpusas M, Hsu YM, Wang JH, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure . 1995;3:1031-1039.